You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. CREATE II: Contextually Relevant Exploitation&Analysis Training Environment

    SBC: APTIMA INC            Topic: OSD11CR2

    Imagery analysts face a number of challenges that complicate their ability to gain contextual awareness, particularly when exploiting multiple forms of sensor data. Faced with adaptable adversaries, analysts require advanced training tools that span a variety of mission contexts. Because no analyst can be an expert in every sensor platform, what is needed is a training tool that senses and adapts ...

    SBIR Phase II 2013 Department of DefenseOffice of the Secretary of Defense
  2. Nomethiazoles Harnessing GABA and NO mimetic activity for Alzheimer's therapy

    SBC: sGC Pharma Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) occurs in one out of eight Americans of age 65 and affects 43% of the elderly over 85. Current FDA-approved drugs only provide symptomatic relief of AD. There is a pressing need to discover newdisease-modifying medications. AD is multifactorial in origin and progression. A drug attenuating several underlying factors is a preferred ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel Insulin Pathway Agonist for Alzheimer's Disease

    SBC: MEDCHEM PARTNERS LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Even though the association of -amyloid peptide (A ) deposition and Alzheimer's Disease (AD) underpins the major hypothesis for disease progression and possibly causation and several drugs addressing the formation or removal of -amyloid plaques have entered clinical trials, no effective therapy exists to date for AD. This reality calls for new targets th ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): In the United States, around 76,250 new cases of melanoma and 9,180 melanoma-related deaths are predicted for 2012. With the therapeutic options currently available, metastatic melanoma patients face the bleak prospectof at best, 10 month's survival and a one-in-ten chance of surviving for 10 years. Surgery and radiation therapy are the mainstay of treatme ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. High Yield Human Hepatocyte Isolation

    SBC: ORGAN SOLUTIONS, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): End-stage liver disease claims about 30,000 lives in the US. Many patients become too ill to tolerate liver transplantation, and even if transplantation were indicated, there is a severe shortage of viable donor organsand only 28% of the wait-listed patients receive transplants. Development and translational studies with novel alternatives to organ transplanta ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Topical Therapeutic to Promote Healing of Chronic Wounds

    SBC: Phoenicia Biosciences, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Chronic refractory, or non-healing, wounds or ulcerations of the extremities represent a major medical condition affecting millions of patients. A chronic wound is defined as a wound that does not show signs of significant healing, or progresses, after use of topical/surgical treatment measures for six months. Non-healing wounds affect 6.5 million patients, aff ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis

    SBC: RIPARIAN PHARMACEUTICALS INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Pharmacological Targeting of Endothelial Dysfunction in Atherogenesis Cardiovascular disease is the leading cause of morbidity and mortality in the United States and is an emerging epidemic world-wide. In particular, atherosclerosis is a life-threatening disease strongly associated with risk factors such as elevated cholesterol levels, high blood pressure and d ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Selective HDAC1/2 inhibitors for hemoglobinopathies

    SBC: ACETYLON PHARMACEUTICALS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The long term goal of this project is a selective Histone Deacetylase 1 and 2 (HDAC1/2) inhibitor for the treatment of patients with the beta-hemoglobinopathies sickle cell anemia and beta- thalassemia. An estimated 400,000 children are born each year with one of these hemoglobin disorders. Few treatments exist to alleviate the symptoms of hemoglobinopathies an ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. A brief iPad-based screening measure for HIV-associated neurocognitive disorders

    SBC: Digital Artefacts LLC            Topic: NIMH

    DESCRIPTION (provided by applicant): HIV-associated neurocognitive disorders (HAND) remain prevalent despite effective anti-retroviral treatments. Cognitive impairments in the current treatment era are often mild and not readily detectable because currentscreening measures (e.g., the HIV Dementia Scale) lack sensitivity to detect subtle impairments in cognitive function. Although more sensitive t ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Neuroinformatics for Prospective Data Management and Sharing

    SBC: ADVANCED BIOMEDICAL INFORMATICS GROUP, L.L.C.            Topic: NIMH

    DESCRIPTION (provided by applicant): There is a tremendous need for tools that allow NIH sponsored investigators to easily share and disseminate data from brain imaging studies. Access to large neuroimaging data sets is a critical aspect of learning abouthow the brain works both in health and disease. Most typically, large data sets are collected by one investigator, used for a specific purpose, a ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government